



ASX ANNOUNCEMENT

Actinogen updated investor presentation

Sydney, 26 November 2018: Actinogen Medical (ASX: ACW, 'the Company') is pleased to release an updated Investor Presentation. The presentation will be used to update shareholders, investors and brokers as part of a non-deal roadshow across Australia. The presentation outlines the key investment highlights, progress and outlook of Actinogen, and is available below.

Key Investment Highlights

- **Novel compound:** Actinogen's lead compound Xanamem has a mechanism of action targeting excess cortisol production in the brain. This cortisol hypothesis and its potential role in Alzheimer's disease has been validated by independent research
- **Targeted strategic market focus:** Alzheimer's disease addressable market worth >US\$7.5bn with unmet needs and potential upside
- **Advanced clinical stage asset:** Fully funded advanced clinical stage program with reported positive safety interim analysis of the XanADu Phase II Alzheimer's study, which has completed patient enrolment and is on track for results read-out in 2Q CY2019.
- **Potential value upside:** Well positioned to unlock further value in Alzheimer's and other indications, supported by significant big pharma interest
- **De-risked opportunity:** Initiated nine additional Xanamem-related studies – all studies fully funded and value-adding to Xanamem data-base. Further pipeline development opportunities under evaluation.
- **Experienced leadership and advisors:** Significant drug development and biotech investment experience guided by key opinion leading clinicians and drug discovery teams

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
 @BillKetelbey

Investor and Media Enquiries

Ben Walsh
WE Buchan
M: +61 411 520 012
E: bwalsh@we-buchan.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11 β -HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. Results are expected in Q2 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.